SGIP21027 / Semaphorin 4D / Mulkerin
Basic Study Information
Purpose:
This trial will assess the safety and tolerability of Pepinemab in combination with
Avelumab in patients with metastatic pancreatic adenocarcinoma that has progressed
after first line chemotherapy. Phase 2 will assess the efficacy of this combination
therapy.
Location: Â鶹ÊÓƵ
Lead Researcher (Principal Investigator)
Lead Researcher:
Daniel Mulkerin
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, Â鶹ÊÓƵ
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search